

Virus-based gene therapy holds promise for neurological disease

New research demonstrates the long term safety and benefit of a [virus](#)-based [gene therapy](#) that has been applied for the first time in a clinical setting. This novel therapy was used to treat young patients with Canavan disease, a devastating inherited neurological condition that typically takes a child's life by age ten. Results of the study have just been published in the journal *Science Translational Medicine*, in an article that describes this first clinical application of a viral-based [gene](#) therapy for a neurodegenerative/neurological disorder.

View the original article here: [Novel virus-based gene therapy holds promise for Canavan disease](#)